{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:44:30Z","timestamp":1792082670055,"version":"4.4.0"},"reference-count":15,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:00:00Z","timestamp":1683072000000},"content-version":"unspecified","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2023,3,30]]},"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:p>Plasmablastic lymphoma (PBL) is a rare subtype of aggressive large B-cell lymphoma, with a dismal prognosis despite aggressive therapies. New approaches are needed for those with refractory disease. PBL expresses antigens similar to multiple myeloma (MM), including B-cell maturation antigen (BCMA). Chimeric antigen receptor T-cell (CAR-T) therapy directed against BCMA has shown efficacy for the treatment of heavily pretreated MM with low rates of grades 3 and 4 cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in a phase Ib\/II trial (A Study of JNJ-68284528, a CAR-T Directed Against BCMA in Participants With Relapsed or Refractory Multiple Myeloma (CARTITUDE-1), <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03548207\">NCT03548207<\/jats:ext-link>). However, data for the use of BCMA CAR-T for treating PBL are lacking.<\/jats:p>\n               <jats:p>We report a challenging case of multiple refractory PBL that emerged from B-cell acute lymphoblastic leukemia in an adolescent who failed to respond to an allogeneic hematopoietic cell transplant. The patient developed rapidly advancing disease despite withdrawal of immunosuppression, treatment with etoposide, ibrutinib, and daratumumab, prompting consideration of BCMA CAR-T (under emergency investigational new drug (eIND)). The patient achieved a complete remission (CR), without recurrent acute graft versus host disease (GVHD), CRS or ICANS after BCMA CAR-T therapy. BCMA CAR-T expansion was detected in vivo, peaking on day 15. The patient remains in CR for more than a year post CAR-T therapy, supporting consideration of immunotherapy for future patients with refractory PBL, a disease with few treatment options.<\/jats:p>","DOI":"10.1136\/jitc-2023-006684","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T11:00:53Z","timestamp":1683111653000},"page":"e006684","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":22,"title":["BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct03548207","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03548207","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03792633","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1149-8524","authenticated-orcid":false,"given":"Sharmila","family":"Raghunandan","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Emory University School of Mecidine, Atlanta, Georgia, USA"},{"name":"Children's Healthcare of Atlanta, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Pauly","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Emory University School of Mecidine, Atlanta, Georgia, USA"},{"name":"Children's Healthcare of Atlanta, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G","family":"Blum","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muna","family":"Qayed","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Emory University School of Mecidine, Atlanta, Georgia, USA"},{"name":"Children's Healthcare of Atlanta, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhav V","family":"Dhodapkar","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Emory University School of Mecidine, Atlanta, Georgia, USA"},{"name":"Winship Cancer Institute, Emory University, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Elkhalifa","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Emory University School of Mecidine, Atlanta, Georgia, USA"},{"name":"Children's Healthcare of Atlanta, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Watkins","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Emory University School of Mecidine, Atlanta, Georgia, USA"},{"name":"Children's Healthcare of Atlanta, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Schoettler","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Emory University School of Mecidine, Atlanta, Georgia, USA"},{"name":"Children's Healthcare of Atlanta, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Horwitz","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Emory University School of Mecidine, Atlanta, Georgia, USA"},{"name":"Children's Healthcare of Atlanta, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhag","family":"Parikh","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Emory University School of Mecidine, Atlanta, Georgia, USA"},{"name":"Children's Healthcare of Atlanta, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanmuganathan","family":"Chandrakasan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Emory University School of Mecidine, Atlanta, Georgia, USA"},{"name":"Children's Healthcare of Atlanta, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Leung","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Emory University School of Mecidine, Atlanta, Georgia, USA"},{"name":"Children's Healthcare of Atlanta, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elyse","family":"Bryson","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Emory University School of Mecidine, Atlanta, Georgia, USA"},{"name":"Children's Healthcare of Atlanta, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Deeb","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Emory University School of Mecidine, Atlanta, Georgia, USA"},{"name":"Children's Healthcare of Atlanta, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L","family":"Kaufman","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Worthington-White","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Emory University School of Mecidine, Atlanta, Georgia, USA"},{"name":"Children's Healthcare of Atlanta, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adina","family":"Alazraki","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Emory University School of Mecidine, Atlanta, Georgia, USA"},{"name":"Children's Healthcare of Atlanta, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan M","family":"Schecter","sequence":"additional","affiliation":[{"name":"Janssen Research and Development LLC, Raritan, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepu","family":"Madduri","sequence":"additional","affiliation":[{"name":"Janssen Research and Development LLC, Raritan, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn C","family":"Jackson","sequence":"additional","affiliation":[{"name":"Janssen Research and Development LLC, Raritan, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Zudaire","sequence":"additional","affiliation":[{"name":"Janssen R&D, Spring House, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agne","family":"Taraseviciute-Morris","sequence":"additional","affiliation":[{"name":"Janssen Research and Development LLC, Raritan, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Babich","sequence":"additional","affiliation":[{"name":"Janssen R&D, Spring House, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonia","family":"Nesheiwat","sequence":"additional","affiliation":[{"name":"Legend Biotech USA Inc, Piscataway, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Vogel","sequence":"additional","affiliation":[{"name":"Janssen Global Services LLC, Raritan, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikoletta","family":"Lendvai","sequence":"additional","affiliation":[{"name":"Janssen Research and Development LLC, Raritan, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lida","family":"Pacaud","sequence":"additional","affiliation":[{"name":"Legend Biotech USA Inc, Piscataway, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten M","family":"Williams","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Emory University School of Mecidine, Atlanta, Georgia, USA"},{"name":"Children's Healthcare of Atlanta, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,5,3]]},"reference":[{"key":"2025100312180733000_11.5.e006684.1","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1182\/blood.V89.4.1413","article-title":"Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection","volume":"89","author":"Delecluse","year":"1997","journal-title":"Blood"},{"key":"2025100312180733000_11.5.e006684.2","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/j.clml.2020.11.025","article-title":"The emerging treatment options of plasmablastic lymphoma: analysis of 173 individual patient outcomes","volume":"21","author":"Makady","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025100312180733000_11.5.e006684.3","first-page":"63","article-title":"Plasmablastic lymphoma: current perspectives","volume":"8","author":"Lopez","year":"2018","journal-title":"Blood Lymphat Cancer"},{"key":"2025100312180733000_11.5.e006684.4","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00277-016-2904-7","article-title":"Refractory plasmablastic lymphoma-a review of treatment options beyond standard therapy","volume":"96","author":"Pretscher","year":"2017","journal-title":"Ann Hematol"},{"key":"2025100312180733000_11.5.e006684.5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-567479"},{"key":"2025100312180733000_11.5.e006684.6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41408-020-0337-y","article-title":"B-cell maturation antigen expression across hematologic cancers: a systematic literature review","volume":"10","author":"Dogan","year":"2020","journal-title":"Blood Cancer J"},{"key":"2025100312180733000_11.5.e006684.7","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00933-8"},{"key":"2025100312180733000_11.5.e006684.8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00842"},{"key":"2025100312180733000_11.5.e006684.9","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/bjh.15156","article-title":"Bortezomib plus epoch is effective as frontline treatment in patients with plasmablastic lymphoma","volume":"184","author":"Castillo","year":"2019","journal-title":"Br J Haematol"},{"key":"2025100312180733000_11.5.e006684.10","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3109\/10428194.2015.1050666","article-title":"Bortezomib plus CHOP for the treatment of HIV-associated plasmablastic lymphoma: clinical experience in three patients","volume":"57","author":"Fernandez-Alvarez","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"2025100312180733000_11.5.e006684.11","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1007\/s00277-016-2732-9","article-title":"Plasmablastic lymphoma: successful management with CHOP and lenalidomide in resource constraint settings","volume":"95","author":"Yanamandra","year":"2016","journal-title":"Ann Hematol"},{"key":"2025100312180733000_11.5.e006684.12","doi-asserted-by":"crossref","unstructured":"Cheng L , Song Q , Liu M , et al . Case report: successful management of a refractory plasmablastic lymphoma patient with tislelizumab and lenalidomide. Front Immunol 2021;12. doi:10.3389\/fimmu.2021.702593","DOI":"10.3389\/fimmu.2021.702593"},{"key":"2025100312180733000_11.5.e006684.13","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000504608","article-title":"Bortezomib- and lenalidomide-based treatment of refractory plasmablastic lymphoma","volume":"43","author":"Ando","year":"2020","journal-title":"Oncol Res Treat"},{"key":"2025100312180733000_11.5.e006684.14","doi-asserted-by":"crossref","first-page":"e559","DOI":"10.1016\/j.clml.2019.06.008","article-title":"Therapeutic potential of checkpoint inhibitors in refractory plasmablastic lymphoma","volume":"19","author":"Damlaj","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025100312180733000_11.5.e006684.15","doi-asserted-by":"crossref","first-page":"E28","DOI":"10.1002\/ajh.25682","article-title":"Axicabtagene ciloleucel for cd19+ plasmablastic lymphoma","volume":"95","author":"Raychaudhuri","year":"2020","journal-title":"Am J Hematol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2023-006684","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:18:13Z","timestamp":1759519093000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2023-006684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":15,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5,3]]},"published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1136\/jitc-2023-006684"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2023-006684","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]}}}